Cost-effectiveness of a collaborative dementia care management-Results of a cluster-randomized controlled trial.

Aged Cooperative Behavior Cost-Benefit Analysis / statistics & numerical data Dementia / therapy Disease Management Female Humans Male Patient Acceptance of Health Care / statistics & numerical data Quality-Adjusted Life Years Surveys and Questionnaires
Alzheimer's disease Collaborative care Cost-effectiveness Costs Dementia Dementia care management Economic impact Economics Formal care Informal care Medical treatment Nonmedical treatment

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
10 2019
Historique:
received: 01 11 2018
revised: 16 05 2019
accepted: 26 05 2019
pubmed: 15 8 2019
medline: 25 8 2020
entrez: 15 8 2019
Statut: ppublish

Résumé

The purpose of this study was to determine the cost-effectiveness of collaborative dementia care management (DCM). The cost-effectiveness analysis was based on the data of 444 patients of a cluster-randomized, controlled trial, conceptualized to evaluate a collaborative DCM that aimed to optimize treatment and care in dementia. Health-care resource use, costs, quality-adjusted life years (QALYs), and incremental cost per QALY gained were measured over a 24-month time horizon. DCM increased QALYs (+0.05) and decreased costs (-569€) due to a lower hospitalization and a delayed institutionalization (7 months) compared with usual care. The probability of DCM being cost-effective was 88% at willingness-to-pay thresholds of 40,000€ per QALY gained and higher in patients living alone compared to those not living alone (96% vs. 26%). DCM is likely to be a cost-effective strategy in treating dementia and thus beneficial for public health-care payers and patients, especially for those living alone.

Identifiants

DOI: 10.1016/j.jalz.2019.05.008 PMID: 31409541
pubmed: 31409541
pii: S1552-5260(19)30149-9
doi: 10.1016/j.jalz.2019.05.008
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1296-1308

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Bernhard Michalowsky (B)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany; Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University, Hamilton, Canada. Electronic address: bernhard.michalowsky@dzne.de.

Feng Xie (F)

Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University, Hamilton, Canada; Program for Health Economics and Outcome Measures (PHENOM), Hamilton, Canada.

Tilly Eichler (T)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany.

Johannes Hertel (J)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany; Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.

Anika Kaczynski (A)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany.

Ingo Kilimann (I)

Department of Psychosomatic Medicine, University Hospital Rostock, Rostock, Germany; German Centre for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Stefan Teipel (S)

Department of Psychosomatic Medicine, University Hospital Rostock, Rostock, Germany; German Centre for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Diana Wucherer (D)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany.

Ina Zwingmann (I)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany.

Jochen René Thyrian (JR)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany.

Wolfgang Hoffmann (W)

German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany; Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald (UMG), Greifswald, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement social › Comportement coopératif › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Organisations et économie des soins de santé › Économie › Coûts et analyse des coûts › Analyse coût-bénéfice › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Prise en charge de la maladie › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Prestations des soins de santé › Attitude envers la santé › Adhésion et observance thérapeutiques › Acceptation des soins par les patients › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Espérance de vie › Années de vie ajustées sur la qualité › Cost-effectiveness of a collaborative dementia...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Cost-effectiveness of a collaborative dementia...